Answers are grounded in this paper and cite their sources.
© Author(s) (or their employer(s)) 2021. Reuse permitted under CC BYNC. No commercial reuse. See rights and permissions. Published by BMJ. INTRODUCTION Treatment response to biologics and targeted synthetic diseasemodifying antirheumatic drugs in rheumatoid arthritis (RA) patients can be classified as primary or secondary nonresponse, based on evidence of an initial response. Conceptually, primary nonresponse is generally considered if the drug was ineffective, with no clinical response within the initial treatment period, while secondary nonresponse would be considered if, after an initial response, the effectiveness is lost over time. Despite these generally accepted definitions, there is no consensus on how to operationalise these concepts. Consequently, the current observational evidence is highly heterogeneous and the prevalence of primary versus secondary failure remains largely unknown. The underlying mechanisms for primary and secondary nonresponse may differ, 5 thus, we believe that defining the type of nonresponse is key to improving patient care. While primary nonresponse may be due to a mechanistic failure, secondary nonresponse may be driven by immunogenicity. Previous studies have shown that both the type of nonresponse and the development of antidrug antibodies (ADAbs) are important factors when predicting the success of the second biologic. 7 Thus, developing clear definitions of how to operationalise primary and secondary nonresponse is essential to accelerate research that aims to predict the optimal therapy for a given patient, which will, in turn, improve clinical practice recommendations. For example, if a patient is a primary nonresponder to a tumour necrosis factor inhibitor (antiTNF), the best practice would likely be to switch to a biologic with different mechanism of action. However, if the patient was able to achieve clinical response prior to failure (secondary nonresponder), it would be reasonable to proceed with another antiTNF. Additionally, following the growing postmarketing research targeting comparative effectiveness of treatments in RA, agreement on operational definitions would improve crossstudy comparisons. Thus, we believe that unifying this terminology would benefit the clinical practice, clinical trials and postmarketing research, and a unique operational procedure for those three scenarios would be ideal. However, since translating clinical concepts into studies in realworld data represents extra challenges, we drive our discussion in the context of observational research. In this viewpoint, we discuss the concepts of primary and secondary nonresponse, with special attention to its implementation in observational data, and we suggest recommendations for future research. Ultimately, we hope this discussion will trigger expert committees to develop standard terminology for these concepts as a step towards harmonising study results.
No takes yet. Share an insight, caveat, or question.
Vallejo‐Yagüe et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: